Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling1

Signaling via Jak2/STAT3 is critically important for normal dendritic cell (DC) differentiation. In addition, we have previously demonstrated that hyperactivation of the Jak2/STAT3 pathway induced by tumor-derived factors (TDF) may be responsible for abnormal DC differentiation in cancer. In this study, using a novel selective inhibitor of Jak2/STAT3, JSI-124, we investigated the mechanism of the Jak2/STAT3 effect on DCs and the possibility of pharmacological regulation of DC differentiation in cancer. Our experiments have demonstrated that JSI-124 overcomes the differentiation block induced by TDF and promotes the differentiation of mature DCs and macrophages. Surprisingly, inhibition of Jak2/STAT3 signaling resulted in dramatic activation of immature DCs generated in the presence of TDF as well as in control medium. This activation manifested in up-regulation of MHC class II, costimulatory molecules, and a dramatic increase in the ability to stimulate allogeneic or Ag-specific T cells. Inhibition of Jak2/STAT3 signaling resulted in activation of the transcription factor NF-κB. This up-regulation was not due to a conventional pathway involving IκBα, but was probably due to a block of the dominant negative effect of STAT3. This indicates that Jak2/STAT3 play an important role in negative regulation of DC activation, and pharmacological inhibition of the Jak2/STAT3 pathway can be used to enhance DC function.

[1]  C. Jobin,et al.  STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells , 2005 .

[2]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[3]  W. Reith,et al.  MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells , 2004, Nature Immunology.

[4]  R. Jove,et al.  Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.

[5]  D. Altieri,et al.  Full-length dominant-negative survivin for cancer immunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  R. Flavell,et al.  STAT3 is required for Flt3L-dependent dendritic cell differentiation. , 2003, Immunity.

[7]  Hua Yu,et al.  A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.

[8]  Bin Yu,et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.

[9]  R. Steinman.  Some interfaces of dendritic cell biology , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  J. Turkson,et al.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. , 2003, Cancer research.

[11]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Wenzheng Zhang,et al.  Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. , 2002, The Biochemical journal.

[13]  Ye Zheng,et al.  Dendritic Cell Development and Survival Require Distinct NF-κB Subunits , 2002 .

[14]  B. Osborne,et al.  Notch-1 Regulates NF-κB Activity in Hemopoietic Progenitor Cells1 , 2001, The Journal of Immunology.

[15]  Antonio Lanzavecchia,et al.  Regulation of T Cell Immunity by Dendritic Cells , 2001, Cell.

[16]  S. Rane,et al.  Janus kinases: components of multiple signaling pathways , 2000, Oncogene.

[17]  R. Steinman,et al.  Transport of peptide-MHC class II complexes in developing dendritic cells. , 2000, Science.

[18]  R. Steinman,et al.  Developmental regulation of MHC class II transport in mouse dendritic cells , 1997, Nature.

[19]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[20]  David Baltimore,et al.  Regulation of the NF-?B/rel transcription factor and I?B inhibitor system , 1993 .

[21]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[22]  Ye Zheng,et al.  Dendritic cell development and survival require distinct NF-kappaB subunits. , 2002, Immunity.

[23]  W. Reith,et al.  The bare lymphocyte syndrome and the regulation of MHC expression. , 2001, Annual review of immunology.

[24]  W. Leonard,et al.  The Jak-STAT pathway. , 2000, Molecular immunology.

[25]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.